Marie‐France Hamou

Author

Marie‐France Hamou

Also Known As

Hamou, Marie-France, M F HAMOU, M F Hamou, M. -F. Hamou, M. F. HAMOU, M. F. Hamou, M. Hamou, M.-F. Hamou, M.F. Hamou, Marie-France Hamou

106

Publications

12K

Citations

H-Index

Concepts

All Affiliations

University Hospital of Lausanne University of Lausanne École Polytechnique Fédérale de Lausanne SIB Swiss Institute of Bioinformatics University Hospital of Zurich

About

Marie‐France Hamou is an author at University Hospital of Lausanne specializing in medicine, tumor biology, and glioma.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	2.4K
2	Cell Biology	16	19	1.8K
3	Engineering	2	2	316
4	Health Sciences	2	2	95
5	Biochemistry	1	1	31

Marie‐France Hamou

Publications

11.9K

Citations

H-Index

Page 1

	Year	Citations
<i>MGMT</i> Gene Silencing and Benefit from Temozolomide in Glioblastoma Monika E. Hegi, Annie‐Claire Diserens, Thierry Gorlia, New England Journal of Medicine	2005	7.1K
Stem Cell–Related “Self-Renewal” Signature and High Epidermal Growth Factor Receptor Expression Associated With Resistance to Concomitant Chemoradiotherapy in Glioblastoma Anastasia Murat, Eugenia Migliavacca, Thierry Gorlia, Journal of Clinical Oncology	2008	728
Classification of human astrocytic gliomas on the basis of gene expression: a correlated group of genes with angiogenic activity emerges as a strong predictor of subtypes. Sophie Godard, Gad Getz, Mauro Delorenzi, PubMed Correlated GroupEngineeringPathologyHigh-grade GliomasCancer Biology	2003	279
Upregulation of Interleukin 8 by Oxygen-deprived Cells in Glioblastoma Suggests a Role in Leukocyte Activation, Chemotaxis, and Angiogenesis Isabelle Desbaillets, Annie‐Claire Diserens, Nicolas de Tribolet, The Journal of Experimental Medicine	1997	241
Anti‐O6‐Methylguanine‐Methyltransferase (MGMT) Immunohistochemistry in Glioblastoma Multiforme: Observer Variability and Lack of Association with Patient Survival Impede Its Use as Clinical Biomarker* Matthias Preusser, Robert C. Janzer, Jörg Felsberg, Brain Pathology Commercial Anti-mgmt AntibodiesPathologyHigh-grade GliomasGliomaTumor Biology	2008	240
Human glioblastoma cells release interleukin 6 in vivo and in vitro. Erwin G. Van Meir, Y. Sawamura, A. C. Diserens, PubMed Human Glioblastoma CellsImmunologyPathologyImmunologic MechanismHigh-grade Gliomas	1990	238
Validation of Real-Time Methylation-Specific PCR to Determine O6-Methylguanine-DNA Methyltransferase Gene Promoter Methylation in Glioma Ilse Vlassenbroeck, Stèphane Califice, Annie‐Claire Diserens, Journal of Molecular Diagnostics Tumor BiologyGliomaEpigenetic ChangeDna MethylationPathology	2008	197
Pathway Analysis of Glioblastoma Tissue after Preoperative Treatment with the EGFR Tyrosine Kinase Inhibitor Gefitinib—A Phase II Trial Monika E. Hegi, Annie‐Claire Diserens, Pierre Bady, Molecular Cancer Therapeutics Tumor InnervationChemoprevention StrategyPathologyPostoperative GefitinibHigh-grade Gliomas	2011	189
Anoxia induces macrophage inhibitory cytokine-1 (MIC-1) in glioblastoma cells independently of p53 and HIF-1 Michele Albertoni, Phillip Shaw, Michimasa Nozaki, Oncogene GliomaRedox RegulatorMedicineImmunologyTumor Suppressor	2002	162
Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without <i>MGMT</i> Promoter Hypermethylation (EORTC 26082) Wolfgang Wick, Thierry Gorlia, Pierre Bady, Clinical Cancer Research	2016	152

Page 1